With further refinement and defined thresholds for treatment, this technology has the potential to guide treatment decisions.

Conference news filled our list this month, dominated by TCT 2024, although two EACTS stories also cracked our top 10.

Fewer rehospitalizations and better functional and QoL outcomes point to TAVI as a good choice, but longer-term data are needed.

The analysis wasn’t prespecified, and with no clear explanation, the field awaits insights from the larger BHF PROTECT-TAVI ...

A new analysis reveals where bleeds are most likely to happen and offers some surprising insights on their link with ...

The inability of QFR to rival FFR for 1-year MACE is a reminder of the need for large studies, even when new tech is enticing ...

Shelley Wood, Ajay Kirtane, and Roxana Mehran look back at key moments, trials, and takeaways from this year's meeting.

Several experts argue that AI-QCA is not a replacement for OCT, but could be valuable in low-resource settings.

The benefit was confined to symptoms, but in a very sick population with few options, that’s important, say researchers.

The result calls into question the prospects of FDA approval for the Acurate neo2 valve, which is already in use globally.

TCT 646: The Aortic Valve Coefficient (AVC) Cut-off Values for Improved Assessment of Aortic Stenosis Severity: A Prospective Study Receive the the latest news, research, and presentations from major ...